By Fineline Cube 
China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany’s Dr. Falk Pharma GmbH to jointly develop ATB102, an innovative aryl hydrocarbon receptor (AhR) agonist for the treatment of moderate to severe ulcerative colitis (UC). ATB102, self-developed by AllianThera, is currently in Phase I clinical trials in the United States.
Collaboration Details
Under the agreement, the two companies will collaborate on advancing the development of ATB102 in the field of inflammatory bowel disease (IBD). Dr. Falk Pharma will have the right to an exclusive global license for manufacturing and commercialization outside of mainland China, Hong Kong, Macau, and Taiwan.
Financial Terms
AllianThera will receive an upfront payment, development and sales milestone payments, and tiered royalties from Dr. Falk Pharma.
ATB102: A Novel Mechanism-of-Action Therapy
ATB102 is a gut-enriched AhR agonist that offers a new mechanism of action for IBD treatment. It has the potential to regulate immune homeostasis, repair the mucosal barrier, and provide anti-fibrotic and antioxidant effects. This innovative therapy aims to provide a new option for UC patients who have an inadequate response to or relapse on existing therapies.-Fineline Info & Tech